Role of SATB2 in Distinguishing the Site of Origin in Glandular Lesions of the Bladder/Urinary Tract

Publication date: Available online 13 July 2017
Source:Human Pathology
Author(s): Giovanna Angela Giannico, Allen M Gown, Jonathan I Epstein, Frank Revetta, Justin A Bishop
The differential diagnosis of glandular lesions of the bladder/urinary tract can be challenging due to significant morphologic and immunohistochemical overlap between primary lesions and metastasis/direct extension from adjacent organs. Special AT-rich sequence-binding protein 2 (SATB2), encoded on chromosome 2q32–33, is a recently described DNA-binding protein involved in osteoblast lineage commitment and expressed in colorectal and appendiceal neoplasms. In this study, we hypothesized that immunohistochemistry for SATB2 may be of value in distinguishing primary adenocarcinoma of the bladder/urinary tract and urothelial carcinoma with glandular differentiation from gastrointestinal and endocervical primaries. Intensity and distribution of SATB2 nuclear labeling was semiquantitatively scored and compared with that of CDX2. The study included 43 primary adenocarcinomas of the bladder/urinary tract, 20 urothelial carcinomas with glandular differentiation, 26 adenocarcinomas of the uterine cervix, and 22 colorectal adenocarcinomas involving the bladder. Positive SATB2 immunostaining was observed in 21/43 (49%) primary bladder/urinary tract adenocarcinomas, 17/22 (77%) colorectal adenocarcinomas, and in the glandular component of 4/18 (22%) urothelial carcinomas with glandular differentiation. SATB2 was negative in 25/26 endocervical adenocarcinomas and showed focal weak immunostaining (1+) in 1/26 (4%). The results were not significantly different from those seen with CDX2. We conclude that SATB2 immunohistochemistry is not useful in supporting urothelial versus gastrointestinal or endocervical origin in the differential diagnosis of glandular lesions of the bladder/urinary tract.



http://ift.tt/2t8cs8g